Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway
Koji Tamada(Yamaguchi University), Lieping Chen(Yale Cancer Center), Yang‐Xin Fu(Xinxiang Central Hospital), Koji Shimozaki(University of Nagasaki), Dallas B. Flies(Mayo Clinic in Arizona), Jian Ni(Zhejiang Normal University), Shigekazu Nagata(The University of Osaka), Gefeng Zhu(Mayo Clinic in Arizona), Hailing Hsu(Amgen (United States)), Andrei I. Chapoval(Human Genome Sciences (United States)), T. Boone(Amgen (United States)), Gabriel Sica(Emory University)
Cited by 307
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex
|Cell|1996|3.1k
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
|Journal of Clinical Investigation|2015|1.4k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k